Cover Image
市場調查報告書

Hemispherx Biopharma, Inc.的產品平台分析

Hemispherx Biopharma, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 192622
出版日期 內容資訊 英文 42 Pages
訂單完成後即時交付
價格
Back to Top
Hemispherx Biopharma, Inc.的產品平台分析 Hemispherx Biopharma, Inc. - Product Pipeline Review - 2015
出版日期: 2015年07月08日 內容資訊: 英文 42 Pages
簡介

Hemispherx Biopharma, Inc.是生物醫藥品企業。該公司致力於病毒及免疫疾病性慢性疾病治療用的醫藥品的開發、製造、商品化。

本報告提供Hemispherx Biopharma, Inc.上的治療藥開發平台現狀及各開發階段比較分析,提供藥物標的,作用機制,給藥途徑,各類型分子的治療藥評估,以及最新的企業新聞和發表,後期階段及中止計劃的相關資訊等。

Hemispherx Biopharma, Inc.的基本資料

Hemispherx Biopharma, Inc.概要

  • 主要資訊
  • 企業資料

Hemispherx Biopharma, Inc.:R&D概要

  • 主要的治療範圍

Hemispherx Biopharma, Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式

Hemispherx Biopharma, Inc.:開發中產品概況

  • 位於最終階段的開發中產品
    • 登記前的產品/聯合治療模式
    • 申請未通過/被撤消的產品/聯合治療模式
  • 位於臨床實驗階段的開發中產品
    • 位於第二階段的產品/聯合治療模式
    • 位於第一階段的產品/聯合治療模式
  • 位於初期階段的開發中產品
    • 位於前臨床階段的產品/聯合治療模式

Hemispherx Biopharma, Inc.:開發階段不明的開發中產品

  • 開發階段不明的產品/聯合治療模式

Hemispherx Biopharma, Inc.:藥物簡介

  • interferon alfa-n3 (human leukocyte derived)
  • rintatolimod
  • Alferon LDO
  • interferon alfa-n3 injection + interferon alfa-n3 low dose oral
  • Oragen

Hemispherx Biopharma, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各類型分子
  • 各作用機制

Hemispherx Biopharma, Inc.:最近的開發平台趨勢

Hemispherx Biopharma, Inc.:暫停中的計劃

Hemispherx Biopharma, Inc.:企業發表

Hemispherx Biopharma, Inc.:總公司和子公司的所在地

Hemispherx Biopharma, Inc.:主要製造設備

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07350CDB

Summary

Global Markets Direct's, 'Hemispherx Biopharma, Inc. - Product Pipeline Review - 2015', provides an overview of the Hemispherx Biopharma, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Hemispherx Biopharma, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Hemispherx Biopharma, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Hemispherx Biopharma, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Hemispherx Biopharma, Inc.'s pipeline products

Reasons to buy

  • Evaluate Hemispherx Biopharma, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Hemispherx Biopharma, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Hemispherx Biopharma, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Hemispherx Biopharma, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Hemispherx Biopharma, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Hemispherx Biopharma, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Hemispherx Biopharma, Inc. Snapshot
    • Hemispherx Biopharma, Inc. Overview
    • Key Information
    • Key Facts
  • Hemispherx Biopharma, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Hemispherx Biopharma, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Hemispherx Biopharma, Inc. - Pipeline Products Glance
    • Hemispherx Biopharma, Inc. - Late Stage Pipeline Products
      • Filing rejected/Withdrawn Products/Combination Treatment Modalities
    • Hemispherx Biopharma, Inc. - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Hemispherx Biopharma, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
    • Hemispherx Biopharma, Inc. - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • Hemispherx Biopharma, Inc. - Drug Profiles
    • rintatolimod
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Alferon LDO
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • interferon alfa-n3
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Hemispherx Biopharma, Inc. - Pipeline Analysis
    • Hemispherx Biopharma, Inc. - Pipeline Products by Target
    • Hemispherx Biopharma, Inc. - Pipeline Products by Route of Administration
    • Hemispherx Biopharma, Inc. - Pipeline Products by Molecule Type
    • Hemispherx Biopharma, Inc. - Pipeline Products by Mechanism of Action
  • Hemispherx Biopharma, Inc. - Recent Pipeline Updates
  • Hemispherx Biopharma, Inc. - Dormant Projects
  • Hemispherx Biopharma, Inc. - Company Statement
  • Hemispherx Biopharma, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Hemispherx Biopharma, Inc. - Key Manufacturing Facilities
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Hemispherx Biopharma, Inc., Key Information
  • Hemispherx Biopharma, Inc., Key Facts
  • Hemispherx Biopharma, Inc. - Pipeline by Indication, 2015
  • Hemispherx Biopharma, Inc. - Pipeline by Stage of Development, 2015
  • Hemispherx Biopharma, Inc. - Monotherapy Products in Pipeline, 2015
  • Hemispherx Biopharma, Inc. - Filing rejected/Withdrawn, 2015
  • Hemispherx Biopharma, Inc. - Phase I, 2015
  • Hemispherx Biopharma, Inc. - Preclinical, 2015
  • Hemispherx Biopharma, Inc. - Unknown, 2015
  • Hemispherx Biopharma, Inc. - Pipeline by Target, 2015
  • Hemispherx Biopharma, Inc. - Pipeline by Route of Administration, 2015
  • Hemispherx Biopharma, Inc. - Pipeline by Molecule Type, 2015
  • Hemispherx Biopharma, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Hemispherx Biopharma, Inc. - Recent Pipeline Updates, 2015
  • Hemispherx Biopharma, Inc. - Dormant Developmental Projects,2015
  • Hemispherx Biopharma, Inc., Subsidiaries
  • Hemispherx Biopharma, Inc., Key Manufacturing Facilities

List of Figures

  • Hemispherx Biopharma, Inc. - Pipeline by Top 10 Indication, 2015
  • Hemispherx Biopharma, Inc. - Pipeline by Stage of Development, 2015
  • Hemispherx Biopharma, Inc. - Monotherapy Products in Pipeline, 2015
  • Hemispherx Biopharma, Inc. - Pipeline by Top 10 Target, 2015
  • Hemispherx Biopharma, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Hemispherx Biopharma, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Hemispherx Biopharma, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top